Clinical Trial Update: Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating valganciclovir (Valcyte) for chronic fatigue syndrome patients with elevated HHV-6 and EBV antibody titers; study com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatigue Syndrome

Drugs mentioned

• Valganciclovir (Valganciclovir)

Snippet

Sponsor: Stanford University | Conditions: Chronic Fatigue Syndrome | Phase 1, Phase 2 | Status: COMPLETED